MADISON,
Wis., Oct. 3, 2023 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the registration
dossier for the CNNC-Accuray joint venture Tomo® C
radiation therapy system for the Type B market has been approved by
the Chinese National Medical Products Administration (NMPA). The
new, made in China system, is the
first joint venture product and represents an important achievement
on behalf of cancer patients, many of whom will need treatment with
radiotherapy at least once to cure their cancer, increase the
chance of cure or relieve symptoms caused by
cancer1.
"The NMPA approval of the Tomo C System represents a tremendous
milestone for Accuray and the CNNC-Accuray joint venture. The
availability of the new system will enable us to expand access to
radiotherapy treatments to cancer patients needing care. Currently,
the number of people requiring radiation treatments in China far outweighs the capacity for
treatment. In fact, the number of systems that deliver radiation
therapy is well below the World Health Organization
recommendations," said Suzanne
Winter, president and CEO of Accuray. "Through our
CNNC-Accuray joint venture we can now offer the Tomo C System, a
fast and effective radiation delivery device, to the largest
segment of the China market,
enabling more medical care teams to provide personalized and highly
precise treatments to more people each day."
The Tomo C platform features helical imaging and radiation
delivery. With fully-integrated treatment planning, centralized
data management and ultra-precise treatment delivery using patented
beam-shaping technology, the system enables greater control of the
radiation dose so it conforms precisely to the tumor and helps
minimize dose to healthy tissue. The system's unique architecture
and high-speed multi-leaf collimator makes it possible for medical
care teams to select from a range of delivery modalities, from
conventionally fractionated to ultra-hypofractionated treatments,
to optimize outcomes for standard radiation therapy indications
including breast, prostate, lung, and head and neck cancers, in
addition to complex treatments such as total marrow
irradiation.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Madison,
Wisconsin, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations and goals
regarding new products, services and innovations, expectations
regarding our joint venture, patient experiences and patient
outcomes. These risks and uncertainties include, but are not
limited to, the effect of the current global economic environment,
including in connection to the COVID-19 pandemic, on the operations
of the company and those of its customers and suppliers; the
company's ability to achieve widespread market acceptance of its
products; the company's ability to develop new products or improve
existing products to meet customers' needs; the company's ability
to anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands;
reliance on third party collaborators, partnerships, strategic
alliances and joint ventures; and such other risks identified under
the heading "Risk Factors" in the company's Annual Report on Form
10-K, filed with the Securities and Exchange Commission (the "SEC")
on September 7, 2023, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1 https://www-pub.iaea.org/MTCD/Publications/PDF/P1638_web.pdf
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-medical-products-administration-301944172.html
SOURCE Accuray Incorporated